Collegium Pharmaceutical (COLL) PT Lowered to $48 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street dips as higher yields, rising oil prices mark shaky start to SeptemberÂ
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Barclays flags an "attractive entry point" in this pharma stock
August 20, 2026 3:00 PM EDTBarclays reiterated an Overweight rating on a pharmaceutical name in a note this week, arguing the roughly 20% share decline since second-quarter results has gone too far.
Collegium Pharma (NASDAQ: COLL) (NASDAQ: COLL) is the stock in question.
"Pain-fueled volatility overdone:... More
